Overview
Pfizer and ALK Positive are collaborating to offer a new grant opportunity seeking proposals for independent medical education initiatives.
Lung cancer remains the most commonly diagnosed cancer worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases1 . Among NSCLC subtypes, advanced ALK-positive NSCLC represents 2% to 7% of NSCLC cases and is characterized by aggressive disease progression and frequent central nervous system involvement2 . Targeted therapies, known as ALK tyrosine kinase inhibitors (TKIs), have transformed treatment outcomes for these patients, improving disease control with a manageable side effect profile.
Through this effort, our goals are to help individuals diagnosed with advanced ALK+ non-small cell lung cancer (NSCLC) by supporting projects that focus on:
• Preparation of patients and care partners for ALK inhibitor therapy, side-effect management, including what to expect during treatment and how to engage with their healthcare team.
• Development of material pertaining to prompt side-effect (adverse events) recognition, including lifestyle recommendations, to preserve / support quality of life.
• Development of tools that emphasize patient preferences, facilitate preference-informed decisionmaking, and ensure inclusivity and accessibility for example: providing multilingual resources.